Published: Jan 05, 2018
Los Angeles –January 4, 2017 – Advanced Bifurcation Systems (ABS) Scott King has joined the leadership team as Vice President of Regulatory Affairs.
ABS is a clinical stage, medical device company whose stenting platform overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties
Mr. King will direct ABS’s regulatory strategy and interface with the FDA as ABS seeks approval of its platform. “Scott brings to ABS over two decades of regulatory affairs and quality assurance experience, with a proven track record leading regulatory affairs for innovative medical device companies,” said Charles Laverty, CEO of Advanced Bifurcation Systems. “His industry expertise will be invaluable as we seek regulatory approval. We look forward to his contributions as a key member of our leadership team.”
Mr. King has extensive experience in setting global regulatory strategy, registration and pre-market notification, agency communications, and inspection and audit management. Prior to joining ABS, Mr. King was VP, Regulatory and Quality Affairs and Chief Compliance Officer at Ceterix Orthopaedics, which produces surgical tools for tissue joint injuries. There King developed the regulatory strategy and prepared the successful submission for the Company’s NovoStitch Plus Meniscal Repair System
Mr. King also drafted and released procedure for evaluating post market product changes, and was responsible for evaluating changes and establishing regulatory strategies to support product research and development.
Prior to joining Ceterix Orthopaedics, Mr. King was Sr. Manager, Product Quality Assurance at Intuitive Surgical, which develops robotic-assisted technologies, tools and services that bring enhanced predictability to surgery.
King’s earlier roles include Associate Director, Regulatory Affairs and Quality Assurance at XDx Molecular Diagnostics (now CareDx), a molecular diagnostics company, and Manager, Quality Systems, at Kyphon (now Medtronic), a maker of spinal treatments.
Mr. King has a BS Biology from James Madison University in Virginia.
About Advanced Bifurcation Systems Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent. For more information, go to www.advancedbifurcation.com.
Contact: Advanced Bifurcation Systems Charles Laverty Chief Executive Officer charles_laverty@advancedbifurcation.com (949)432-4824
